<DOC>
	<DOCNO>NCT01670136</DOCNO>
	<brief_summary>The purpose study learn safety dose sildenafil infant .</brief_summary>
	<brief_title>Pharmacokinetics Sildenafil Premature Infants</brief_title>
	<detailed_description>Pharmacokinetics safety sildenafil study preterm infant receive sildenafil per standard care 1 dose prescribe study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Cohort 1 : Gestational age 28 week less receive sildenafil standard care &lt; 365 postnatal day Cohort 2 : Gestational age 28 week less 728 postnatal day age Mechanical ventilation nasal continuous positive airway pressure ( NCPAP ) highflow nasal cannula Intravenous line place Cohort 1 : Any condition would make participant , opinion investigator , unsuitable study Cohort 2 : Previous exposure sildenafil within 7 day prior enrollment Any condition would make participant , opinion investigator , unsuitable study History allergic reaction sildenafil AST &gt; ULN ALT &gt; 3x ULN Currently vasopressor hypotension Known sickle cell disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>364 Days</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sildenafil</keyword>
	<keyword>preterm infant</keyword>
	<keyword>persistent pulmonary hypertension newborn</keyword>
</DOC>